The Supreme Court has heard oral arguments in a high‑stakes case over whether thousands of lawsuits against Bayer, the owner of Monsanto and maker of the Roundup herbicide, can proceed in state courts. At issue in Monsanto Co. v. Durnell is whether federal pesticide law and Environmental Protection Agency–approved labeling preempt state‑law failure‑to‑warn claims brought by cancer patients and their families, who allege that exposure to glyphosate in Roundup caused non‑Hodgkin lymphoma and other cancers. Both liberal and conservative coverage agree that the justices appeared divided as they questioned whether Bayer can avoid liability by pointing to federal regulators’ prior determinations that glyphosate is not likely to be carcinogenic, and whether allowing the suits could unleash or sustain a multibillion‑dollar wave of damages. Reports across the spectrum also note that outside the Court, hundreds of advocates and cancer survivors demonstrated, arguing that Roundup’s risks were downplayed and that consumers were not adequately warned.

Liberal and conservative outlets alike situate the case within the broader framework of federal versus state authority over health and safety regulation, focusing on how the Supreme Court’s ruling could reshape the relationship between EPA determinations and state tort law. Both sides emphasize that the Court’s decision will have major implications for corporate liability, product labeling standards, and the future of pesticide regulation, with potential ripple effects on other chemicals and consumer products. Coverage also converges on the political stakes: the case has drawn in the federal government, with prior administrations’ positions scrutinized, and it intersects with public health advocacy movements that frame the litigation as a test of how far courts will go in deferring to federal agencies. Across the spectrum, the litigation is presented as a bellwether for future mass‑tort cases and as a key moment in defining who bears responsibility for warning the public about contested health risks.

Areas of disagreement

Regulatory deference and preemption. Liberal‑aligned outlets tend to stress that EPA assessments are not infallible, highlighting scientific disputes over glyphosate and portraying state‑court lawsuits as an essential backstop when federal regulators are seen as too lenient or captured by industry. Conservative coverage more often underscores the need for a uniform national standard, giving greater weight to EPA’s conclusion that glyphosate is not likely carcinogenic and warning that allowing divergent state‑law warnings would undermine regulatory coherence and burden interstate commerce. While liberal reporting frames preemption arguments as an attempt to shield Bayer from accountability, conservative stories are more likely to frame them as a defense of Congress’s chosen regulatory scheme.

Corporate accountability and risk. Liberal sources typically foreground plaintiffs’ stories and public‑health advocates, depicting Bayer/Monsanto as having long minimized or obscured potential dangers, and arguing that sizable verdicts are necessary to deter corporate misconduct and compensate victims. Conservative outlets acknowledge the emotional testimony of cancer survivors but more often stress the risk of expansive liability based on contested science, warning this could chill innovation, drive up costs for farmers and consumers, and reward plaintiffs’ lawyers. Where liberal coverage casts the lawsuits as a corrective to corporate power, conservative coverage tends to frame them as part of a litigation wave that may exceed what the evidence reliably supports.

Political framing and government role. Liberal‑aligned reporting generally criticizes government support for Bayer, especially when advanced by Republican administrations, presenting it as favoring corporate interests over public health and grassroots health movements. Conservative stories are more divided: some criticize the Trump administration’s backing of Bayer as a betrayal of health‑focused initiatives like the Make America Healthy Again movement, while others emphasize the administration’s alignment with regulatory agencies and business interests as a principled stance on economic growth and regulatory certainty. Liberal outlets tend to highlight protests and activist pressure as democratic accountability, whereas conservative outlets are more likely to describe them as part of broader anti‑chemical or anti‑corporate campaigns with electoral implications.

Science and uncertainty. Liberal coverage often points to international cancer research bodies and independent scientists who have raised red flags about glyphosate, arguing that scientific uncertainty should cut in favor of transparency and stronger warnings for consumers. Conservative coverage more frequently spotlights studies and regulatory reviews that have not found conclusive evidence of carcinogenicity at typical exposure levels, portraying the litigation as running ahead of the science and susceptible to “junk science” in jury trials. Liberals frame uncertainty as a rationale for precautionary state action and tort remedies, while conservatives frame it as a reason to defer to expert federal agencies rather than heterogeneous jury verdicts.

In summary, liberal coverage tends to emphasize corporate accountability, skeptical scrutiny of federal regulators, and the role of state courts and activists in protecting public health, while conservative coverage tends to stress regulatory uniformity, deference to EPA’s scientific judgments, and the economic and legal risks of expansive tort liability for Bayer and similar companies.